Under the terms of the agreement, Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics ... expedite the process by 6-18 months and ...
Under the terms of the agreement, Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics’ proprietary ... expedite the process by 6-18 months ...
US-based Candid Therapeutics has signed another T-cell engager (TCE) partnership, this time with Chinese biotech WuXi Biologics for the global rights to a preclinical asset. Under the deal ...
Dr. Chris Chen, CEO of WuXi Biologics, commented, "We’re glad to enable Candid to advance the progress of T-cell engagers through WuXiBody TM. This collaboration not only showcases the platform ...
CDMO WuXi Biologics signed a deal with Candid Therapeutics, a clinical-stage biotechnology company, giving Candid exclusive global rights to a preclinical trispecific T-cell engager discovered on ...
Under the terms of the agreement, Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics' proprietary universal ... expedite the process by 6 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback